Published in Breast Care (Basel) on November 25, 2008
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med (2006) 9.85
The global burden of chronic diseases: overcoming impediments to prevention and control. JAMA (2004) 8.25
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol (2005) 6.90
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol (2002) 4.32
A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol (1991) 3.96
The value meal: how to save $1,700 per month or more on lapatinib. J Clin Oncol (2007) 3.74
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol (2007) 3.36
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol (2003) 3.34
Cost of cancer care: issues and implications. J Clin Oncol (2007) 3.00
"Westernizing" women's risks? Breast cancer in lower-income countries. N Engl J Med (2008) 2.85
Commentary: Epidemiology on the side of the angels. Int J Epidemiol (2002) 1.97
Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol (2005) 1.60
Review of North-South and South-South cooperation and conditions necessary to sustain research capability in developing countries. J Health Popul Nutr (2003) 1.49
Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. J Clin Oncol (2006) 1.47
Phase I-II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer. Anticancer Drugs (2005) 1.24
Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer (2002) 1.24
Cancer initiatives in developing countries. Ann Oncol (2006) 1.18
Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events. Pharmacogenet Genomics (2006) 1.14
Cancer in the developing world: a call to action. BMJ (1999) 1.07
Essential drugs for cancer therapy: a World Health Organization consultation. Ann Oncol (1999) 1.05
Ongoing challenges of a global international patient assistance program. Ann Oncol (2006) 1.03
Disparities in cancer care: a worldwide perspective and roadmap for change. J Clin Oncol (2006) 1.02
Delay in seeking medical advice and late presentation of female breast cancer patients in most of the world. Could we make changes? The experience of 23 years in port said, egypt. Breast Care (Basel) (2008) 0.99
Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. J Clin Oncol (1997) 0.97
Treatment of breast cancer in countries with limited resources. Breast J (2003) 0.96
Developing a global strategy for cancer. Eur J Cancer (1999) 0.94
Hormone receptor and HER-2 expression in breast cancers among Sub-Saharan African women. Breast J (2008) 0.93
A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors. Invest New Drugs (1997) 0.93
Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast Cancer. Breast Care (Basel) (2008) 0.92
Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study. Anticancer Drugs (1999) 0.90
Pharmacokinetics of Navelbine oral in elderly patients. Tumori (2002) 0.84
A global strategy for radiotherapy: a WHO consultation. Clin Oncol (R Coll Radiol) (1999) 0.83
Oral vinorelbine (Navelbine) in the treatment of advanced breast cancer. Semin Oncol (1995) 0.80
Poor nations need more help to slow growing cancer burden: the International Atomic Energy Agency asks donors to provide millions of dollars to buy radiotherapy equipment. Lancet (2003) 0.80